Opendata, web and dolomites

EASY-Diabetes SIGNED

Individualised and Equitable Care of Type 2 Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EASY-Diabetes" data sheet

The following table provides information about the project.

Coordinator
ADJUVIA AB 

Organization address
address: TROLLEBERGSVAGEN 13
city: LUND
postcode: 22229
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADJUVIA AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

EASY – Diabetes is a digital health solution that helps patients with Type 2 diabetes and health care providers analyse data and make better decisions about therapies by accessing a carefully curated global database based on clinical data and medical evidence collected over the course of nine years and powered by machine learning algorithms and other forms of artificial intelligence. We offer EASY-Diabetes as a Software-as-a-Service to healthcare providers at a fee of €50 per patient per year. Diabetes is a prevalent and costly chronic disease, affecting 425 million people worldwide. Although 9.2% of the health care budget in Europe spent on diabetes, the results for patients remain inadequate even in the most advanced healthcare systems. Patients lack a patient-centred and personalised approach to disease management. 90% of patients with T2D are treated by GPs in primary care. Most clinics lack both the manpower and the expertise required to deal with the needs of patients for regular contact with health care providers and the complexity of diabetes treatment. Existing eHealth solutions show some crucial drawbacks, such as lack of clinical validation against the standard of care, no personalised medical treatment options, not being drug agnostic. Our team brings together demonstrated expertise in medicine, clinical trials, drug development, regulatory affairs, product development, programming, machine learning, business development. The SME Phase 1 Feasibility study will aim to complete the validation of the commercial feasibility of Easy – Diabetes with target market segments and key stakeholders. We will strengthen our financial planning and IP protection strategy necessary to improve our service and refine our go-to-market strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASY-DIABETES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EASY-DIABETES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More